Index

Accessory palpebral gland, 5, 6, 7, 8
Acetylcysteine
  as mucolytic agent, 225
  in Sjögren's syndrome, 163
N-acetylneuraminic acid, 77
  in human tears, 41
Adapette, 223, 224, 227, 285
Adapt, 223, 224, 227, 228, 285
Agar diffusion test, of lysozyme, 36, 39
Alacrima, congenital, 173–174
Albumin
  in lipid film, 84
  in tears, 34, 35, 131
Alkaline burn
  glucose in tears, 124, 125
  lipid content of tears, 138
  protein fractions in tears, 130, 132, 134, 136
  proteins in tears, 126, 127, 128
Amino acids
  in human tear lysozyme, 39
  in tear glycoprotein of rabbit, 42
  in tears, 33
Ampulla, 17
Anesthesia
  and Riley-Day syndrome, 165
  topical, and corneal microvilli, 101
Anhidrotic ectodermal dysplasia, 175
Anomalies, congenital, 19–21
Antibiotics, topical, in erythema multiforme, 172
Antibodies
  antinuclear, in Sjögren's syndrome, 162
  in tears, 61–65
Antihistamines, and corneal drying in contact lens wearers, 260
Antiviral chemotherapy, ocular-insert therapy in, 235
Aqueous phase of tear film, 85–86
Arcus senilis, 28
Argyral, in measuring retention time, 224
Arteritis, and Sjögren's syndrome, 161
Arthritis, rheumatoid, and Sjögren's syndrome, 158, 161
Arthus, phenomenon of, 48
Astigmatism, contact lenses in, 247–249
Autonomic nervous system, dysfunction in Riley-Day syndrome, 165
Avitaminosis A, 185
  and dry eye syndrome, 236

Bacillus prodigiosus, in measuring tear flow, 109
Basic secretion test, 13, 202
Bell's phenomenon, absence of, 192
Benzalkonium chloride
  in artificial tears, 224
  in wetting solutions, 285

Bilirubin, concentration in tears, 124
Blepharitis, and lipid content of tears, 138
Blepharoconjunctivitis, inorganic ion concentration in, 120
Blinking
  and anesthetic corneas, 193
  compromise of, and tear film breakup, 97
  and corneal sensation in formation of dry spots, 154
  in distribution of tear fluid, 85
  and dry spots, 150
  flow rate of tears between scleral lens and cornea, 254
  incomplete, and localized desiccation, 283
  interference with, 191
  and lens desiccation, 271
  partial, and dry spots, 150–151, 152–153
  and thickness of precorneal tear film, 104, 105
BMP. *See* Pemphigoid, benign mucosal
Bonnet-Cochet ethesiometer, 99
BP polymer, 285
Breakup time, 186, 187–188. *See also* Corneal wetting time
  defined, 97
  distribution, in normal individuals, 99, 100
  distribution of, standard deviations, 99
  measurement technique, 98–101
BSM. *See* Mucin, Bovine Submaxillary
Burns, facial and lid, scleral molded lenses in, 258
BUT. *See* Breakup time
Calcium in tears, 31, 120
Canaliculi, 16–17
  in tear drainage, 110–112, 113–114
Canaliculus test, 214–215
Capillarity and tear drainage, 110
Carbohydrate in tear glycoprotein of rabbit, 41
Carbon dioxide, in soft contact lenses, 272
Carcinoma, medullary thyroid, 177
Cataract, proteins in tears, 128
Catheter, in tear drainage measurements, 111, 112
Cationic surfactants in wetting solutions, 285
Cellulose ethers in artificial tears, 223
Central nervous system diseases, in lacrimal hyposecretion, 174
Ceruloplasmin in tears, 35
Chlamydia agent antibodies in tears, 61
Chloride in tears, 31, 120
Cleaning solutions for hydrogel lenses, 270
Clinistix R, 123
Cocaine in basic secretion test, 202
Congenital familial sensory neuropathy, 177
Conjunctiva
  in benign mucosal pemphigoid, 167–168
  surface irregularities and dry spots, 151
Conjunctival biopsy, 206–207
Conjunctival mucus, fractions of mucins, 77
Conjunctival surface, exchanges across, 106–107
Conjunctivitis
  bacterial, glucose in tears, 124, 125
  inorganic ion concentrations in, 120, 121, 122

lipid content of tears, 138
protein fractions in tears, 130, 132, 133, 134, 136
proteins in tears, 126, 128
viral, glucose concentration in, 123, 124, 125
inorganic ion concentration in, 120, 121, 122
lipid content of tears, 138
protein fractions in tears, 130, 132, 133, 134, 136
proteins in tears, 126, 128
Connective tissue disease, and Sjögren's syndrome, 161
Contact angle, 74
Contact lenses
apertures in, 249
in astigmatism, 247–249
in dry eye conditions, 257–259
edges of, 249
effects of tear film, 255–256
effects on cornea, 250
hard, 263–265
critical surface tension, 280
hydrophilic, solid deposits on, 255
integrity, 255–256
major forces applied to, 250, 251
major indications for, 247
materials for, 263–276
molded scleral, 258
position of, 250–253
soft, in dry eye syndromes, 228
hydrophilic, 267–276
hydrophilic corneal, 258
hydrophobic, 265–267
as ocular inserts, 231
permeability, 272
therapy in benign mucosal pemphigoid, 169
and surface chemistry, 279–286
and surfacing abnormality, 195–196
three major types of, 280
Coproantibody, 49
Cornea
in benign mucosal pemphigoid, 168
in congenital alacrima, 173
in erythema multiforme, 171
irregular, with contact lens, 248
as major refracting element, 253
surface irregularities, and dry spots, 151
Corneal anesthesia, 192–193
in Riley-Day syndrome, 166
Corneal epithelium
damaged by preservatives, 224
energy-making devices, 253
hydrophobic nature of, 73
keratinization of, 192
wettability of, 74–77
wetting mechanism of, 85–87
Corneal sensation, measurements in breakup time, 99
Corneal surface, hydrophobic character of, 90
Corneal wetting time, 97, 211–212
Corticosteroids
in benign mucosal pemphigoid, 169
in erythema multiforme, 172
in Sjögren's syndrome, 163
Cranial nerves, congenital palsy of, in congenital alacrima, 174

Dacryocystography, 215–216
Dacryocystorhinostomy procedure, 110, 111
Dacryostenoses, 21
DCR. *See* Dacryocystorhinostomy procedure
Delivery methods, for artificial tears, 241
Dellen, production of, 194, 195

Diabetics, glucose in tears, 123, 124, 125
Disjoining pressure, and stability of thin films, 87
Distributional system, 14–16
Drugs
  and devices for constant-rate release, 232
  used in clinical tests, 216
Dry eye conditions
  aqueous vs. mucin deficiency, 225
  caused by contact lenses, 259–260
  mucin-deficient, 185–188
  ocular-insert therapy, 235
  treatment with contact lenses, 257–259
Dry spots, 211
  formation mechanism, 97
  in precorneal tear film, 150
Ducts, excretory, 7
Dye test
  primary, 12, 213–214
  secondary, 214
Dysautonomia, familial. *See* Riley-Day syndrome

Edge effect, in contact lens wear, 279–280
Electrophoresis
  acrylamide gel, and tear proteins, 35
  agarose, of human tears, 129, 134
  of tears, 51
Electrolytes in tears, 31–32
Emollient solutions, 222
Enzyme activity of tears, changes in eye diseases, 138
Epimyoepithelial islands, 162
Epiphora
  causes of, 212
  diagnosis of, 12
Equilibrium spreading pressure, 82–84
Erosions, epithelial, related to spotwise drying, 152, 154
Erythema multiforme
  epidemiology, 170–171
  histopathology of, 172
  major, 170
  minor, 170
Erythrocyte sedimentation rate, in Sjögren's syndrome, 162
ESP. *See* Equilibrium spreading pressure
Eyelids. *See* Lids

Fatigue block, tearing in, 13–14
Fatty acids, overproduction of, 27
Females
  vs. males, differences in tear composition, 131
  protein concentrations in tears, 127
Fibrinolysin as mucolytic agent, 225
Film pressure of oil, 81–82
Film(s)
  aqueous, stability of, 87–88
  duplex, 80–81, 82
    of meibomian secretion, 83
Flexsol, 285
Fluids
  body, relative water content, 30
  ocular, concentration of inorganic ions, 32
Fluorescein
  in contact lens fitting, 256–257
  test, in Sjögren's syndrome, 159
Fluorexon, 257
Foramen, lacrimal, 6, 7
Fungi, and hydrogel lenses, 270

Gamma globulin in tears, 51, 52

Gaule spots, in Riley-Day syndrome, 166
Glaucoma, ocular-insert therapy in, 234
Globulin, in tears, 34, 35
Glucose, in tears, 32–33, 123–124, 125
Glycoproteins
  in mucoid layer, 40–44
  mucous, surface chemical study of, 78
  relative carbohydrate and protein contents, 42–43
Goblet-cell deficient syndromes, and ocular-insert therapy, 237
Goblet cells, counting of, 206
Gougerot's syndrome. *See* Sjögren's syndrome
Gravity, and tear drainage, 110

Hashimoto's thyroiditis, and Sjögren's syndrome, 161
Hasner's valve, 18
HEMA. *See* 2-Hydroxyethyl methacrylate
Henle, crypts of, 3, 4
Hepatobiliary disease, chronic, in Sjögren's disease, 161
Herpes simplex of cornea, antibodies in tears, 62–63
Hexosamine, measurement of, 208–209
Histamine, in Riley-Day syndrome, 165
Holmes-Adie syndrome. *See* Pupillotonia-areflexia
Homovanillic acid, in urine, in Riley-Day syndrome, 165
HPMC. *See* Hydroxypropylmethylcellulose
Hydrocortisone, in ocular-insert therapy, 235
Hydrogel contact lenses, 267
  contamination by pathogens, 268, 270
  relative permeability and percent hydration, 273
Hydrogen bond formation, and wettability of corneal epithelium, 76
Hydrogen ion concentration of tear fluid, 122
Hydrophilic solids, water films on, 88, 91
Hydrophobic solids, water films on, 88, 89
Hydroxyethylcellulose, in wetting solutions, 284
2-Hydroxyethyl methacrylate, in soft contact lenses, 267, 275
Hydroxypropylcellulose, in artificial tears, 227
Hydroxypropylmethylcellulose
  in artificial tears, 227
    in measuring retention time, 224
  in wetting solutions, 284
Hypergammaglobulinemia, and Sjögren's disease, 162
Hypersecretion, diagnosis of, 12
Hyposecretion, diagnosis of, 12, 13
Hypovitaminosis A, 175–176

Icterus, and bilirubin concentration in tears, 124
IgA
  serum antibodies, 49–50
  in tears, 35, 52, 53, 54, 55, 135, 137, 138
IgD, role in tear film, 64
IgE
  in tears, 53, 60, 64
  as reaginic antibody, 60
IgE immunoglobulin, 50
IgG in tears, 35, 52, 53, 54, 55, 135, 138
IgG-IgA levels, variations in, 57
IgM level in tears, 53, 56
Immunity, of eye, acquired, 51
Immunization, local, 48–49

Immunoelectrophoresis, and tear proteins, 36
Immunoelectrophoretic studies, 52
Immunoglobulins in tears, 51–60, 137
  average levels, normal vs. disease states, 58
  levels in various morbid states, 59
Indian children, high serum immunoglobulin levels, 60
Inferior rectus muscle, 14
Inflammation, and immunoglobulin levels, 56, 58
Inflammatory eye diseases
  external, pH of tears, 122
    protein concentration in tears, 127
    and protein fractions in tears, 133
  external and internal, tear composition in, 119
Infusion-type devices, 239–243
Ion concentrations, inorganic, changes due to eye diseases, 120–122
Iridocyclitis
  glucose in tears, 125
  inorganic ion concentration in, 120, 121, 122
  lipid content of tears, 138
  protein fractions in tears, 130, 132, 134, 136
  proteins in tears, 126, 127, 128
Iritis
  glucose in tears, 125
  inorganic ion concentration in, 120, 121, 122
  lipid content of tears, 138
  protein fractions in tears, 130, 132, 134, 136
  proteins in tears, 126, 127, 128

Jews, Ashkenazic, and Riley-Day syndrome, 164

Keratitis
  exposure, 191–192
  filamentary, in Sjögren's syndrome, 159
  neuroparalytic, 192–193
    molded scleral lens in, 258
  viral, glucose concentration in, 123, 124, 125
    inorganic ion concentration in, 120, 121, 122
    lipid content of tears, 138
    protein fractions in tears, 130, 132, 133, 134, 136
    proteins in tears, 126, 128
Keratitis sicca, and dry spots, 154–155
Keratoconjunctivitis sicca, 27. *See also* Sjögren's syndrome
  lysozyme level in tears, 39
  mucous secretion in, 225
  rose bengal staining in, 204
  secondary to sarcoidosis, 173
Keratomalacia, 176
Kidney disease, and uric acid in tears, 124
Krause, accessory lacrimal glands of, 3, 4, 14
  in production of tears, 119

Lacrimal diaphragm, 18
Lacrimal excretory ducts, 16, 17
Lacrimal excretory system
  anatomy of, 16–19
  embryology of, 16
Lacrimal fluid, 103
  distribution of, 104–105
  observation of flow, 107
  removed by lacrimal ducts, 19
Lacrimal glands
  changes in Sjögren's disease, 162
  IgA in, 54, 55
  in immunology of tear film, 63
  in production of tears, 119

two forms of secretion, 103
Lacrimal hyposecretion, paralytic, 174
Lacrimal irrigation test. *See* Dye test, secondary
Lacrimal nerve, 9, 11
Lacrimal pump, 18–19
Lacrimal sac, pressure recording from, 113
in tear drainage measurement, 112–114
Lacrimal secretors, 3
Lashes, inturned, and contact lenses, 259
Lens desiccation, 271
Lesions, in erythema multiforme, 171
Leukopenia, in Sjögren's syndrome, 162
Levator aponeurosis, lateral horn of, 5, 6
Levator palpebrae superioris muscle, 7, 14
Lid-corneal surface incongruity, 194–196
Lid margin, defects in, and dry spots, 151–152
Lids
bridge-over effect of, 195
in distribution of lacrimal fluid, 14
holding of, effect on breakup times, 100
Lipid contamination, of contact lenses, 282
Lipid content of tears, changes in eye diseases, 137–138
Lipid film, over aqueous tear layer, 82
Lipid layer, superficial, 86
formation and role of, 80–85
Lipid-mucin, lipid protein interactions, 84–85
Lipids
and breakup of tear film, 282
defined, 24
measurement of film pressure, 82
neutral, 25
Lipid secretions (meibomian)
composition of, 24–27
functions of, 23
Lipophilic substances, absorption by silicone lenses, 267
Liquid films, stability of, 87
Liquifilm, 227
Local Immunization (monograph), 48
Lupus erythematosus, systemic, in Sjögren's syndrome, 161
Lymphoepithelial lesion, benign, in Sjögren's syndrome, 162, 163
Lymphoid mantle, of conjunctiva, in immunology of tears, 63
Lymphoma, and Sjögren's syndrome, 160
Lysozyme
agar diffusion test, 209–210
biological activity of, 36
decreased in Sjögren's syndrome, 162
relative amounts in tears and other substances, 51
in tears, 34, 35, 36–40, 50–51
concentration in diseased patients, 38
in external inflammatory eye diseases, 138
normal concentrations, 37

Magnesium, in tears, 31
Maier, sinus of, 17
Main lacrimal duct, cross section of, 11
Main lacrimal gland, 5, 6
upper surface of, 10
Manz, glands of, 3, 4
Marangoni flow, 91
Mechanical devices, for administration of tear substitutes, 239–244

Meibomian glands, 4, 23
and lipids, 137
in production of tears, 119
Meibomianitis, 27
Meibomian secretion
film pressure–area isotherm of, 83
ESP of, 83
importance of, 27–28
Methylcellulose
in artificial tears, 223, 227
in wetting solutions, 284
Methyl methacrylate, 263
Microorganisms, relative size and average pore diameter of hydrogel lenses, 269
Mikulicz's syndrome, and Sjögren's syndrome, 160, 163, 173
MMA. *See* Methyl methacrylate
Mobile devices, patient-worn, 240
Moll, glands of, 4
Motor mechanism, congenital anomalies of, 21
Mucin
action in enhancing wetting, 77–80, 284
adsorbed effect on wettability of lenses, 282
aqueous solution, oil-water tensions, 79
Bovine Submaxillary, 78
surface activity of, 78–80
diffusion of, 85
reduction in production of, 185–188
Mucin deficiency, and ocular-insert therapy, 236
Mucin secretors, 3, 4
Mucoid, rabbit tear, molecular weight and elution volume, 41, 43
Mucoid layer
inorganic constituents of, 40–44
as part of tear film, 40
Mucolytic agents, 225
Mucopolysaccharides, in mucoid layer, 40
Mucus
migration rate, 209
qualitative assay, 207–208
quantitative test, 208–209
substitute replacement, 169
tests for, 203–209
Muramidase. *See* Lysozyme
Myopathy, and Sjögren's disease, 161

Nasolacrimal duct, 17–18
congenital obstruction of, 20
Naturalens, 267, 275
Neomycin, in measuring retention time, 224
Neoplasms, lymphoid, and Sjögren's syndrome, 161
Neuroma, multiple mucosal, 177
Nutrition-deficient diseases, and dry eye syndrome, 236

Ocular inserts
basic concepts, 231–234
constant-rate release, 233
current studies, 234–237
Ocusert, 232, 234, 235, 237
Oil, on water surface, 80–81
Oil secretion, 15–16
Oil secretors, 4
Oral mucosa, in benign mucosal pemphigoid, 168–169
Orbicularis oculi muscle, 14, 16
and tear drainage, 110
Orbital lobe. *See* Main lacrimal gland
Organic constituents of tears
of high molecular weight, 33–40
of low molecular weight, 32–33

Oxygen
diffuse flux through soft lenses, 266
partial pressure differences, 274
needs of cornea, and contact lenses, 256
permeability coefficients in water, 275
and soft contact lenses, 272

Palpebral lobe. *See* Accessory palpebral gland
Parasympathomimetic drugs, in diagnosing Riley-Day syndrome, 166
PCTF. *See* Tear film, precorneal
Pemphigoid
benign mucosal, 167–169
molded scleral lenses in, 258
ocular, absence of conjunctival goblet cells, 207
Pemphigus vulgaris, 167
pH of tears, 31, 122, 221
PHEMA. *See* Poly(2-hydroxyethyl methacrylate)
Pheochromocytoma–medullary thyroid carcinoma syndrome, 177–178
Phosphate concentration in human tears, 120
Phospholipids, in meibomian secretion, 25
Pilocarpine, prolonged release in glaucoma, 234
PMMA. *See* Poly(methyl methacrylate)
Polyarteritis nodosa, and Sjögren's syndrome, 161
Poly(2-hydroxyethyl methacrylate), in soft contact lenses, 267
Polymers
in artificial tears, 226
cross-linked. *See* Xerogels
water-soluble, in artificial tears, 223
in wetting solutions, 284
Poly(methyl methacrylate)
composition of, 264
in contact lenses, 257, 263–265
Polyvinyl alcohol
in artificial tears, 223, 227, 228
in wetting solutions, 284–285
Poly(vinyl pyrrolidone) in soft contact lenses, 267
Poly(vinylmethyl ether), in artificial tears, 227
Potassium in tears, 31, 120
Prealbumin, specific tear, 35, 36
Precorneal film, three layers of, 15
Presert, 224
Preservatives, role in artificial tears, 224
Primary dye test. *See* Dye test, primary
Proparacaine
in basic secretion test, 202
effect on breakup time, 99, 100, 101
in rose bengal staining, 203
Protein fractions
distribution in tears from eye diseases, 127–137
six groups in human tears, 129
Proteins
percent ascribed to immunoglobulins in tears and serum, 65
simple, surface chemistry of, 78
as tear constituent, 30
changes in eye diseases, 125–127
concentration of, 209–210
and immunoglobulins, 53–60
origin of various fractions of, 34, 35
types of, 34

Proteinuria, in Sjögren's syndrome, 162
Pseudoepiphora, diagnosis of, 12, 13
Pulmonary fibrosis, and Sjögren's disease, 161
Pump(s), as infusion devices, 240–243
  Fairchild miniature, 240–241
  Model MLG, 240
  Sage, 242–243
Puncta, multiple, 20
Punctum, 17
Pupillotonia-areflexia, 176
PVA. *See* Polyvinyl alcohol

Raynaud's phenomenon, and Sjögren's syndrome, 161
Reflex secretion, psychogenic type, 11, 13–14
Reflex system, retinal stimulation by light, 10
Refraction, index of, of cornea and tears, 248
Regurgitation test, 213
Retention time
  in conjunctival sac, 223
  measurement of, 223
Rheumatoid factor, in Sjögren's syndrome, 162
Rhinovirus-15, and antibodies in tears, 62
Riley-Day syndrome, 163–167
Rose bengal stain, 203–204
  in Sjögren's syndrome, 159

Salivary gland(s)
  in sarcoidosis, 173
  in Sjögren's syndrome, 160, 162
Salk vaccine, action of, 47–48
Salpix, 215
Sarcoidosis, 173
  and Sjögren's syndrome, 160
Scalded skin syndrome. *See* Toxic epidermal necrolysis
Schirmer lysoplate method, 39
Schirmer tear test strips, 201
Schirmer test for Sjögren's syndrome, 159–160
Schirmer test 1, 12, 200–202
Schirmer test 2, 13, 202–203
Schirmer test 3, 204–205
Sclerosis, progressive systemic, in Sjögren's syndrome, 161
Schwalbe, inferior ligament of, 6
Scurvy, and Sjögren's syndrome, 161
Sebaceous glands
  compared with meibomian, 27
  secretion, high spreading pressure of, 86
Sebum, ESP of, 83
Secretion, basal, 200
Secretogogs, 12
Secretors
  basic, 3–5
  reflex, 5–12, 200
    failure of, 13
    nerve pathways of, 8–10
Secretory embarrassments, diagnosis of, 12–14
Secretory piece, in tears, 60
Secretory system, 3–12
  immunology of, 47–50
Segmental hypohidrosis, 176
Serum, leakage into tears, 57, 58
Serum albumin, in tears, 35
Serum antibody, in immunity, 47–48
Sialic acid, concentration in human tears, 42
Silicone
  critical surface tension, 280
  and poly(oxyethylene) as emollient solution, 222
Silicone rubber for soft contact lenses, 265
Sinografin, 215
Sjögren's syndrome, 157–163. *See also* Keratoconjunctivitis sicca

histopathology, 162–163
laboratory findings, 161–162
pathogenesis, 163
vs. sarcoidosis, 173
soft contact lenses in, 259
Sleep
basic secretion in, 5, 14
and tear drainage, 115–116
Sodium, in tears, 31, 120
Sodium chloride, effect on gel contact lenses, 268
Soemmering's ligament, 6, 7
Soflens, 267, 275
Spectacle frames, in infusion devices, 242
Spreading coefficient, oil on water, 80–81
Sterilization of hydrogel lenses, 270
Stevens-Johnson syndrome. *See also* Erythema multiforme, major
keratoplasty in, 194
molded scleral lenses in, 258
mucus assay in, 208
STP. *See* Prealbumin, specific tear
Surface-active substance, molecules of, 284
Surface chemistry
and stability of tear film, 73
and tear film research, vii–viii
Surface tension, 74
critical, and contact angle of water, various solid surfaces, 75
definition of, 75
Surfacing mechanism, defects in, 191–197
Symblepharon formation, 193–194

Tarsal glands. *See* Meibomian glands
Tear drainage mechanism, 115
Tear film
as biosurface of cornea, 29
breakup of, 97–102
mechanism of, 90, 91. *See also* Breakup time
and contact lenses, 275–276
described, vii
formation and stability of, 73–96
postlens, 252
precorneal, formation mechanism, 91–92
physiological properties of, 149–154
and products of epithelial metabolism, 272
role in contact lens wear, 247–262
stability of, 87–92, 97
and contact lens wear, 279
tests of, 210–212
and topical anesthetics, 101
structure of, 85–86, 199–200
Tear flow
normal, and epithelial erosions, 155
vectors of, 107–108
Tear fluid
dynamics of, 104–109
macromolecular components, 33
Tears, 103
absence of, in Riley-Day syndrome, 165–166
artificial, 221–229
evaluation of, 226–227
in treatment of keratoconjunctivitis sicca, 163
circulation, clinical evaluation of, 256–257
composition of, 119
drainage mechanism, 110–116
excretion, tests of, 212–216
function in holding contact lenses, 250
nonspecific antibacterial action of, 50–51
quality of, tests of, 205

Tears—*Continued*
quantity of, tests of, 199–205
reduced, and occurrence of dry spots, 150
relative water content, 30
secretion rate, 108–109, 200
surface tension value, 280, 282
Tear sac, 17–18
Tear system, three parts of, 3
Teflon, exposure to mucin solution, 80
TEN. *See* Toxic epidermal necrolysis, 170
Tests, clinical, 199–217
3 to 9 o'clock staining, 195, 283
Thrombotic thrombocytopenic purpura, and Sjögren's syndrome, 161
Thymidine, in measuring retention time, 223
Tonicity of eye drops, and irritation, 221–222
Toxic epidermal necrolysis, 170
epidemiology, 170–171
Trachoma, 61–62, 236
Transferrin, in tears, 35
Trauma, ocular, and decreased immunoglobulin level, 59–60
Trichiasis, 151
of upper lid, 155

Ultracentrifugal analysis of tear fluid, 53
Ultraviolet irradiation
glucose in tears, 124, 125
lipid content of tears, 138
protein fractions in tears, 130, 132, 134, 136
proteins in tears, 126, 127, 128
Urea in tears, 33
Uric acid, concentration in human tears, vs. serum, 124

Vaccinia virus, antibodies in tears, 63
Vanilmandelic acid, in Riley-Day syndrome, 165
Vascular permeability, increased, induction of 48
Vertebrates
and basic secretion, 5
peripheral sensory type of reflex secretion, 10
Viscosity, effect on retention time, 223

Waldenström's hyperglobulinemic purpura, and Sjögren's syndrome, 161
Water
evaporation, and lipid films, 84
percentage in tears, 30–31
surface tension, 283
Wettability
of contact lenses, 280–283
of solids, 74
Wetting agents, commercial synthetic, 76–77
Wetting solutions
for contact lenses, 283–285
hard lenses, 264
silicone lenses, 265
Wolfring, accessory lacrimal glands of, 3, 4, 14
in production of tears, 119

Xerogels, 268

Zeis, glands of, 4
and lipids, 137
in production of tears, 119

Index

Acetazolamide therapy, 16, 17, 116
  contraindications, 17
Acetylcholine
  and hypotension, 152
  and intraocular pressure, 89
  reaction to, 152, 153
Adjuvant drugs, 15, 18
  acetazolamide, 16, 17
  administration of, 16
  ganglionic blocking, 15–16
  and local anesthesia, 158–161
Air embolism, 179, 180
Akinesia, 170–171
  Atkinson, 143–146
  O'Brien, 143–146
  regional blocks, 143–148
  Van Lint, 143–146
Allergies, 49, 51, 102, 109, 180. *See also* Systemic toxicity
  to acetylcholine, 152, 153
  to lidocaine, 39
  to narcotics, 64. *See also under specific drug name*
  to paraben, 48
  to procaine, 38, 39
Amide-linked local anesthetics. *See* Lidocaine; Mepivacaine
Anemia
  acute, 103
  in children, 126
  chronic, 103
  iron deficiency, 103
  physiological, 102, 103
    acute, 103
    chronic, 103
  postoperative, 205
  sickle cell, 205, 206
Anesthesia. *See also* General anesthesia; Local anesthesia; Regional anesthesia; Topical anesthesia; *under specific agent*
  in adults, 83–97
  general technique, 90–95
    and specific operations, 95–97
  and intraocular pressure, 21–30
  and muscle relaxants, 21–30
  pediatric, 99–128
  pharmacology, of local agents, 35–57
  and physiology, of the eye, 1–18
Anticholinesterase. *See specific agent*
Apnea, 26, 115
Aqueous humor, and intraocular pressure, 9–11
Arrhythmias, 104, 112, 113, 149–158, 179, 180, 184, 199
  from digitalis, 72
  from epinephrine, 154
  paroxysmal, 68
  ventricular, 72
Arterial hypertension, 7, 89. *See also* Hypertension
Arterial hypotension, 94. *See also* Hypotension
Arteriosclerosis, 85, 95, 164
Asphyxia, 17
Asystole, 177, 178, 180, 184
Atkinson akinesia technique, 143–146
Atrial fibrillation, 61, 85, 160
Atropine, 24, 25, 30, 109, 110, 149, 151, 152
  for bradycardia, 96, 153
  and general anesthesia, 78, 79
  intoxication, 110
  and intraocular pressure, 9
  in pediatric surgery, 114, 115, 117
  postoperative, 94

Atropine—*Continued*
as premedication, 74, 77, 78, 90, 91
sulfate, 184

Barbiturates, 27, 40, 64, 73, 107, 108, 110, 111. *See also* Sedatives; Tranquilizers
in pediatric surgery, 117
pentobarbital, 75–77
pentothal, 23
phenobarbital, 76
for premedication, 74, 91
and respiratory depression, 107
thiopental, 23, 111, 117, 151
Viadril, 23
Vistaril, 23
Belladonna derivatives. *See under specific agent*
Blindness, 4, 204, 209
Bradycardia, 96, 108–110, 115, 149–151, 177, 179, 199
from acetylcholine, 152
from digitalis, 72
from fentanyl, 161
sinus, 184
Brain death, clinical, 185
Burns, 163, 178, 179

Carbon dioxide administration, 17
Cardiac arrest, 149, 153, 177–180
and hyperkalemia, 178
and mortality, 216
recognition of, 180, 181
resuscitation, 177–186
Cardiac disease, congenital, 124, 126
Cardiac dysrhythmias, 94–97
Cardiac failure, 85, 89
Cardiovascular disease, 64, 68, 89, 193
arrhythmias, 104, 112, 113, 149–153, 157, 158, 179, 180, 184, 199
congestive failure, 68, 104, 207
and mortality, 216, 225
Cardiovascular evaluation, 68–70
Cataract, 26, 29, 170
congenital, 6, 100
and diabetes mellitus, 85
extraction of, 84, 101, 152, 154, 165
mortality, 217, 220–225
and general anesthesia, 29
traumatic, 6
Cerebral hypoxia, 184
from obesity, 202
Cerebral palsy, 105
Circulatory collapse, 71, 184
from reserpine, 72
Circulatory complications, hypotensive, and hypovolemic, 206
Circulatory depression, 210
Cocaine, 35, 37, 83, 97
complications of, 56
pharmacology of, 55, 56
Complications, of ophthalmic anesthesia, 177
air embolism, 179, 180
cardiac arrest, 177–180
cardiac catheterization, 180
from cocaine, 56
congestive heart failure, 68, 104, 207
coronary occlusion, 180
drug interaction, 70–74, 84, 85, 152–157
electrical, 161–163
burns, 163
macroshock, 162
microshock, 162
pacemaker deviation, 163
electrolyte disturbances, 178
hemorrhage, 80, 88, 155, 164, 165
hypercapnia, 67, 177, 179
hypovolemia, 179
from inadequate anesthesia, 170, 171
from nonanesthetic drugs, 178, 179
oculocardiac reflex, 77, 90–97, 109, 112, 116, 149–152
optic atrophy, 148, 165–169
in postoperative care, 198–211
prevention, 163
vagal reflex mechanisms, 177, 178
Congestive heart failure, 68, 104, 207
Corneal opacities, 4

Coronary artery disease, 69
Coronary occlusion, 180
Coughing, 5, 9, 22, 25, 29, 43, 88, 94, 104
  with halothane, 95
  during insufflation, 118
  and intraocular hemorrhage, 66
  during intubation, 92, 93, 120, 121
  postoperative, 87, 204
  and preoperative patient evaluation, 64, 67
  smoker's, 64, 66
Curare, and intraocular pressure, 9, 25. *See also d*-Tubocurarine
Cyanosis, 66, 181, 194, 199

Death. *See also* Mortality
  biological, 186
  brain, clinical, 185
Dehydration, 103, 104
Descemet's membrane, wrinkled, 4
Diabetes, 164
  and cataracts, 85
  juvenile, 104, 126
  therapy, 190
Digitalis, treatment with, 68, 185
  toxicity of, 69, 72
Diplopia, 23, 26
Diuretics, treatment with, 68
Drug interaction, 70–74, 85, 152–157. *See also* Allergies; Systemic toxicity; *and under specific agent*
  anticholinesterase agents, 73
  antihypertensives, 72
  digitalis, 72
  hypoglycemic agents, 85
  monoamine oxidase inhibitors, 73
  steroids, 71, 72

Edema, 208
  laryngeal, 121
  pulmonary, 156, 211
  subglottic, 120, 212
Enophthalmos, 9, 27
Epilepsy, 105
Epinephrine, 97, 113, 185
  and arrhythmias, 154
  for heart failure, 90
  intracardiac, 184
  with local anesthetics, 44–47
  in pediatric anesthesia, 121
Essential hypertension, 7
Ester-linked local anesthetics. *See* Cocaine; Procaine; Tetracaine
Exophthalmos, 8

Fibrillation, atrial, 61, 85, 160
  ventricular, 160, 178–180
    in asystole, 184
Friedenwald nomogram, 3

Gallamine, 151, 154
General anesthesia, in adults, 83–97
  and hemorrhage, 90
  and intraocular tension, 87–90
  and mortality, 215–226
  and oculocardiac reflex, 90, 91
  and patient type, 85–87
  requirements, 87–90
  and specific operations, 95–97
    dacryocystorhinostomy, 96
    glaucoma, 96
    penetrating injuries, 95, 96
    retinal detachment, 97
    squint, 96
  technique, 90–95
    apparatus, 93
    extubation, 95
    induction, 91, 92
    intubation, 92, 93
    maintenance, 93–95
    monitoring, 95
    premedication, 90–91
    recovery, 95
Glaucoma, 7, 28, 30, 74, 77, 84, 96
  acute, 4, 14, 24
  in children, 124
  chronic, 1, 6, 23, 24
  congenital, 100
  narrow-angle, 14
  open-angle, 154
  subacute, 29
  wide-angle, 14, 24, 27, 28

Goldmann applanation tonometry, 2

Halothane, 25, 63, 79, 94, 96, 107, 152, 153, 158
  disadvantages, 94, 95
  with epinephrine, 154
  hepatitis, 63, 113
  in pediatric ophthalmology, 112, 114, 128
  recovery time, 94, 210
  substitute, 114
  and vomiting, 93
Heart failure. *See* Cardiac failure
Hemorrhage, 4
  expulsive, 88
  intraocular, 88
  reduction of, 90
  retrobulbar, 165
  subarachnoid, 155
Hepatitis, from halothane, 63, 113
History taking, 63–65
  hospital questionnaire, for child, 129–130
Hypercapnia, 67, 177
  from obesity, 179
Hypercarbia, 21, 179
  postoperative, 194, 202
Hypersensitivity. *See* Allergies; Systemic toxicity
Hypertension, 70, 73, 86, 156, 157
  arterial, 7, 89, 199
  essential, 7
  intraocular, 28
  pulmonary, 180
  systemic, 7
  treatment of, 69, 70
Hyperthermia, malignant, 64, 112, 158
Hyperventilation, 17
Hypnotics, 22
Hypotension, 23, 73, 85, 95, 177, 179
  from acetylcholine, 152
  arterial, 94
  induced, 96
  from narcotics, 75
  postoperative, 206, 208, 210
  from steroids, 71
Hypothermia, 15, 17, 18
Hypoventilation, 17, 18, 21, 119, 158, 159
  with general anesthesia, 90
  from narcotics, 202
Hypovolemia, 179
Hypoxemia, 21, 67, 177, 184
  postoperative, 194, 199, 202–204, 211
Hypoxia, 17, 18, 103, 179
  cerebral, 184
  from obesity, 202
  postoperative, 191, 194, 198–201, 210

Inadequate anesthesia, 170, 171
Infection, 71, 103, 112, 120, 121
  mortality, 215, 222
Inhalation agents
  chloroform, 25
  cyclopropane, 25
  ether, 25
  halothane, 25, 63, 79, 94, 96. *See also* Halothane
  with narcotics, 75
  nitrous oxide, 24, 25, 94, 151
  with oxygen, 28, 93, 96, 113, 191
  in pediatric surgery, 113, 114, 117, 128. *See also* General anesthesia, in adults
Intraocular hemorrhage, 88
Intraocular hypertension, 28
Intraocular pressure
  and anesthesia, effects on, 21–30
    central nervous system depressants, 22–23
    narcotics, 23, 24
  changes in, 6–15
    aqueous humor, 9–15
    blood, 7–9
    fluid content, 7
    lens, 6
    semisolid contents, 6
    tumor, 6
    vitreous humor, 6
  control of, 4
  and corneal opacities, 4

and Descemet's membrane, 4
and glaucoma, 1–7, 23, 24, 28, 30
acute, 4
and hemorrhage, 4
hypothermia, effects of, 17, 18
importance of, 3, 4
and inhalation agents, 25
and intracranial pressure, 3
and loss of vision, 4
and loss of vitreous, 4
maintenance of, 4–15
measuring methods, 1–3
direct, 2
Goldmann applanation tonometry, 2
Schiotz indentation tonometry, 3
and muscle relaxants, 25–29. *See also* Muscle relaxants, and intraocular pressure
and neuroleptanesthesia, 24–25
normal, 1
and outside pressure, 5
during lid closure, 5
in muscular contraction, 5
in orbital tumor, 4, 5
in venous congestion, 5
and prolapse, of iris and lens, 4
and scleral flaccidity, 3
and scleral rigidity, 2, 3, 5, 6
ventilation, effects of, 17, 18
Intraoperative complications, 149–171
drug interaction, 152–157
electrical hazards, 161–163
inadequate anesthesia, 170–171
monitoring of, 157–158
oculocardiac reflex, 149–152
retrobulbar injection, 164–170. *See also* Complications, of ophthalmic anesthesia
Iris prolapse, 4

Juvenile diabetes, 104, 126

Ketamine, 22, 23, 29, 30, 91, 114, 191, 192
in pediatric surgery, 117, 128

Laryngeal edema, 121
Laryngeal tumors, 65
Lens prolapse, 4
Lidocaine, 35, 37, 38, 45, 52, 54, 184
allergy to, 39
complications of, 38, 51, 53
pharmacology of, 42, 43
systemic toxicity to, 39, 40
Local anesthesia
Atkinson technique, 143–146
cocaine, 35, 37, 55, 56, 83, 97
lidocaine, 35–40, 51–54, 184
mepivacaine, 35, 37
O'Brien akinesia, in children, 124, 143–146
in pediatrics, 124
pharmacology of, 35–57
procaine, 35–42
tetracaine, 35, 37, 50–53
Van Lint technique, 143–146. *See also* Topical anesthesia

Macroshock, 162
Maintenance
of anesthesia
in adults, 93–95
of pediatric patients, 118–122
of intraocular pressure, 4–15
Malignant hyperthermia, 64, 112, 158
Mepivacaine, 35, 37
pharmacology of, 44, 45
Microshock, 162
Monitoring, 157–158, 196
blood pressure, 112, 157
cardioscope, 157
Doppler monitor, 113
electrocardiograph, 112
with general anesthesia, 95
for outpatients, 193, 207
pediatric patients, 111–113
precordial stethoscope, 112, 157
thermistor thermometer, 112
Mortality, 78, 79, 215–226
during cataract surgery, 217–225
from congestive heart failure, 207
and general anesthesia, 213–226
from myocardial infarctions, 216, 217

Mortality—*Continued*
from strabismus surgery, 217–224
and surgical risk, 222–225
and type of surgery, 220–222
Muscle relaxants, and intraocular pressure, 21–30
barbiturates, 23
curare, 25, 26
decamethonium, 29
gallamine, 26
inhalation agents, 25
narcotics, 23, 24
neuroleptanesthesia, 24, 25
succinylcholine, 26
Mydriasis, 8, 14, 54, 56
Myocardial infarction, 69, 85, 179
and mortality, 216, 217
postoperative, 208
Myopia, 6

Narcotics, 22, 107, 109–111, 160, 191, 193. *See also under specific drug*
allergy to, 64
and hypertension, 73
and hypotension, 75
hypoventilation from, 202
morphine, 23
for outpatients, 211
for premedication, 74, 76, 77, 91, 94
meperidine, 75
opium, 75
and respiratory depression, 108
side effects, 75
with tranquilizers, 76
Narrow-angle glaucoma, 14
Neuroleptanesthesia, 21, 23, 158, 159
atropine, 24, 25
droperidol, 24
fentanyl citrate, 24
scopolamine, 24
succinylcholine, 22–28
Neuroleptic agents. *See* Neuroleptanesthesia
Nitrous oxide, 24, 25, 94, 151
with narcotics, 75
with oxygen, 28, 93, 96, 113, 191
in pediatric surgery, 113, 114, 117, 128
Norepinephrine, 38, 44

Obesity, and hypercapnia, 179
O'Brien akinesia, 143–146
Oculocardiac reflex, 90, 109, 112, 116, 149–152
and bradycardia, 96
and general anesthesia, 90, 91
during monitoring, 95
and premedication, 77
and retinal detachment, 97
Open-angle glaucoma, 154
Optic atrophy, 148, 165–169
Optic nerve injury, 164–165
anatomical studies, 166–168
animal studies, 168–170
Orbital tumor, 4, 5, 54
Outpatients
pediatric ophthalmic, 125–128
instructions to parents, 134
record form, 132–133

Paroxysmal arrhythmias, 68
Pediatric anesthesia, 99–128
anesthetic agents, 113–115
breathing devices, 122–123
and humidification, of gases, 122, 123
developmental stages of patients, 100–101
premature, 100
three months to six years, 100, 101
induction techniques, 117, 118
local anesthesia, 124
maintenance, 118–122
endotracheal intubation, 119–122
insufflation, 118, 119
management, and monitoring, 111–113
medical problems, 103–106
diabetes, 104, 105
heart disease, 104
muscular disorders, 105, 106
neurological disorders, 105, 106
steroid therapy, 105
temperature elevation, 103, 104

muscle relaxants, 115
outpatients, 125–128
anesthesia, 128
instructions to parents, 127, 134
preoperative preparation, 127, 128
record form, 132–133
recovery and discharge, 128
preanesthetic preparation, 101–111
history and examination, 101, 102
laboratory studies, 102, 103
medication, 107–111
restriction of fluids, 106, 107
technique, 123, 124
and age of patient, 124
duration, 123
and type of operation, 123, 124
and type of patient, 124
Penetrating injuries, 95, 96
Pharmacology, of local agents
on cardiovascular system, 38
on central nervous system, 38
hypersensitivity, 38, 39. *See also* Allergies
metabolism and excretion, 36, 37
site and mode, 36
and systemic toxicity, 39–45. *See also* Systemic toxicity
topical anesthesia, 47–56
Pharyngeal tumors, 65
Physiology of eye, and anesthesia, 1–18
control of, 4–15
importance of, 3, 4
measuring methods in, 1–3
Friedenwald nomogram, 3
Goldmann applanation tonometry, 2
Schiotz indentation tonometry, 1, 3
and normal pressure, 1
Pilocarpine hydrochloride, 24
Postoperative care, 189–212
complications, 198–211
circulatory, 206–208
neurological, 208, 209
pain, 209
respiratory, 198–206
vomiting, 210
immediate recovery, 192–198
intensive observation, 194
for outpatients, 211, 212
recovery, intraoperative factors, 191, 192
Premedication, 62, 74–78, 131
for adults, 90–91
barbiturates, 23. *See also under specific drug*
muscle relaxants, 25–29
narcotics, 23–24. *See also under specific drug*
neuroleptanesthesia, 24, 25
for pediatric patients, 107–111
Preoperative preparation of patients, 61–79
cardiovascular evaluation, 68–70
drug therapy, influence on anesthesia, 70–74
examination, 65
history taking, 63–65
laboratory tests, 70
premedication, 74–78, 131. *See also under specific agent*
rapport with patients, 62, 63
risk, 78, 79
Procaine, 35, 37
allergy to, 38, 39
drug interactions with, 40
pharmacology of, 40–42
Prolapse, lens, 4
Pulmonary disease, 65
and general anesthesia, 65
and narcotics, 75
Pulmonary edema, 156, 211
Pulmonary evaluation of patient, 65
Pulmonary hypertension, 180

Regional anesthesia, 45, 139–148
nerve supply, 139–142
regional blocks, 142–148
akinesia, 143–148
analgesia, 143–148
Renal disease, 17
Renal insufficiency, 178

Respiratory acidosis, 18
Respiratory arrest, 181
Respiratory depression, 75, 91, 93, 159, 177
  from barbiturates, 107
  from narcotics, 108, 202, 203
  from obesity, 202, 203
  postoperative, 191, 193, 201, 204, 210
Respiratory disease, 64, 65, 103
  chronic, 190
  and cough, 87. *See also* Pulmonary disease
Resuscitation, 177–186
  cardiac arrest factors, 177–180
    air embolism, 179, 180
    anesthetic drugs, 177
    cardiac catheterization, 180
    cardiac disease, 180
    coronary occlusion, 180
    electrolyte disturbances, 178
    hypercapnia, 179
    hypovolemia, 179
    nonanesthetic drugs, 178, 179
    vagal reflex mechanisms, 177, 178
  cardiopulmonary, 181–185
    additional therapy, 183–185
    emergency treatment, 181–183
    evaluating effectiveness of, 185, 186
  recognition of need, 180, 181
Retinal detachment, 6, 84, 97
Retrobulbar hemorrhage, 165
Retrobulbar injection, 164–170

Schiotz indentation tonometry, 3
Scleral flaccidity, 3
Scleral rigidity, 2–6
Scopolamine, 24, 30, 108, 109
  in elderly, 91
  intoxication, 110
  for premedication, 74, 77, 108
Sedatives, 90, 91, 94, 107, 110, 193. *See also* Barbiturates; Tranquilizers
Sickle cell anemia, 205, 206
Smoker's cough, 64, 66
Steroids, 121
  drug interaction with, 71–72
  hypotension from, 71
Strabismus, 21, 113, 116, 140
  correction, in children, 101, 114, 124
    mortality from operations, 217, 220–224
Subarachnoid hemorrhage, 155
Subglottic edema, 120, 212
Succinylcholine, 4, 17, 26–30, 37, 64, 65, 109, 151, 178
  as central nervous system depressant, 22
  contraindications, 153, 158
  drug interaction with, 73, 74
  and intraocular pressure, 16, 28
  and loss of vision, 4
  in pediatric anesthesia, 112, 115, 116
Supplemental drug therapy, with local anesthesia, 158–161
Systemic hypertension, 7
Systemic toxicity, 39–45. *See also* Allergies; Drug interaction; *and under specific agent*
  to dibucaine, 55
  from digitalis, 69, 72
  from halothane, 63
  to lidocaine, 39, 40
  from narcotics, 75

Tachycardia, 109, 150, 179, 199
  postoperative, 208
  ventricular, 160
Temperature elevation, 110
  from dehydration, 103, 104
Tetracaine, 35, 37, 50, 51
  corneal toxicity to, 51
  and hyperemia, 53
Thiopental, 23, 111, 117, 151
Tonometry, 30
  Goldmann, 2
  Schiotz, 3

Topical anesthesia, 47–56
  Holocaine, 48
  lidocaine (Xylocaine), 52
  Nupercaine, 48
  phenacaine, 53, 54
  piperocaine, 53
  tetracaine, 50
Tranquilizers, 22, 83, 159, 193. *See also* Barbiturates; Sedatives
  with narcotics, 76, 77
  for premedication, 74, 76, 77, 90, 91
  with regional anesthesia, 77
Trauma, 120, 121, 178, 179
  and morbidity, 123
d-Tubocurarine, 21, 26–28, 151
  in pediatric surgery, 116, 154. *See also* Curare, and intraocular pressure
Tumors
  congenital, 100
  of larynx, 65
  orbital, 4–6
  of pharynx, 65

Van Lint akinesia technique, 143–145
Vascular congestion, 21
Venous congestion, 5
Venous obstruction, 22
Ventricular arrhythmias, 72
Ventricular fibrillation, 160, 178–180, 183
Ventricular tachycardia, 160
Vitreous loss, 4, 27
Vitreous tumor, 6
Vomiting, 5, 25, 88, 91, 161
  and halothane, 93, 113
  postoperative, 210

Index

Adenosine triphosphatase studies, 46–47
Amacrine cells, in retinal nuclear layer, 217, 221, 224
Anterior chamber angle, 109–128
  electron microscopy of, 116–125
  function of, 109
  glaucoma and, 112–113
  light microscopy of, 113–116
  surgery of, 109, 112
Astroglia, in intraocular portion, 230–231, 235
Aqueous humor
  outflow of, 120–121, 124
  reabsorption of, 131
Artifacts, 16, 30–31, 159
Autoradiography, 33–36
Axons, in intraocular portion, 230–231

Barkan membrane, 124–125
Barrier systems, electron microscopic identification of, 43
Basal lamina, 173–179, 235
Basement membranes, 76–77
Bipolar cells, in retinal nuclear layer, 216–217
Bowman's layer, 98–99
Bruch's membrane, 189–190, 191–195, 196, 199, 200, 208
  layers of, 193, 200

Cell, structure and function of, 53–78
Cell fractionation, 37–38
Cell membrane, 56, 58, 70–73
Choriocapillaris, 190, 192
Choroid, 189, 190, 191, 192, 195, 196
  arteries of, 190, 197
  choriocapillaris of, 192
  veins of, 190–192, 198
Ciliary body, 157–166
  electron microscopy of, 158–166
  epithelium of, 158, 159–160, 162–164
  functions of, 157–158
  light microscopy of, 158
  muscle of, 158, 161, 166
  stroma, 158, 160–161, 165
Ciliary glands. *See* Moll, glands of
Ciliary secretory cells, 257–260
Cloquet's canal, 179–181
Clump cells, 131, 134
Collagen fibrils, 77–78, 104, 120
  in vitreous, 169, 171–172, 174, 178, 179
Cone, 209
Cone pedicles, 211, 215, 218
Conjunctiva, 85–90
  bulbar, 86–87
    epithelium of, 86, 88, 89, 90
    stroma of, 86–87
  fornical and tarsal, 87, 88
  goblet cells of, 252–255
Cornea, 93, 95–104
  anterior epithelium of, 95–98, 99
  Bowman's layer of, 98–99
  Descemet's membrane of, 101–102, 103
  endothelium of, 102–104
  stroma of, 100–101
Corneal-scleral meshwork, 116, 117, 120
Cristae, 63, 64
Critical point processing, 25–27, 29
Cytoplasmic inclusions, 69–70

Cytoplasmic organelles, 56, 57–69. *See also specific structures, e.g.,* Endoplasmic reticulum; Mitochondria; Ribosomes

Dehydration, tissue, 5–6, 26
Dendritic melanocytes, 131, 136, 139
Descemet's membrane, 72, 76, 101–102, 103
Desmosomes, 74, 75, 96, 97, 160, 164
Dilator muscles, of iris, 131, 132
DNA (deoxyribonucleic acid), 55, 59–63
Drugs, molecular actions of, 54
Drusen, 193

Elastic fibers, 78
Electron histochemistry, 46–47
Electron microscopy
  anterior chamber angle and, 116–125
  and barrier systems, identification of, 43
  ciliary body and, 158–166
  iris and, 132, 134, 135, 136–141
  retina and, 207–208, 212, 213, 214, 218, 219, 220, 224, 225, 226
  scanning, 19–31. *See also* Scanning electron microscope
    development of, 20–22
    interpretation in, 30–31
    secondary electrons in, 22–24
    tissue preparation for, 24–29
    tissue reclamation and, 28–29
  specialized techniques in, 33–47. *See also specific techniques*
    autoradiography, 33–36
    electron histochemistry, 46–47
    freeze cleaving, 41–43
    shadow casting, 38–41
    sucrose density gradients, 37–38
    tracer studies, 43–46
  transmission, 3–16. *See also* Transmission electron microscope
    artifacts in, 16
    basic principles of, 8–11
    development of, 3–4
    tissue preparation for, 4–8
Electron transport particles (ETP), 64
Embedding, tissue, 6, 7
Endoplasmic reticulum, 56, 57–59
  channels, 57–59
Endoskeleton, 69
Extracellular structures, 76–78
Extraocular muscle, 263–270
  fast fibers in, 263, 265, 266, 269, 270
  internal structure of, 264–265
  myofibrils in, 264–269
  sarcoplasmic reticulum of, 264–270
  slow fibers in, 263, 265, 267–268
  transverse tubular system of, 264–265, 269, 270

Ferritin, 43
Filaments, fine, 56, 68–69
Fixation, tissue, 5, 6, 25–26
Freeze cleaving, 41–43
Freeze drying, 27
Freon-13 critical point technique, tissue preparation procedures for, 25–27, 29

Gap junctions, 76, 160, 163
Genetic code, 60–62
Glands. *See* Ocular adnexa, glands of; Sebaceous glands
Glaucoma, 112–113, 123, 124, 126
Glia cell detachment, 183
Glutaraldehyde, 5, 25–26
Glycogen particles, 63, 70
Goblet cells, 252–255
Golgi complex, 56, 63, 65–66

Heat-etching technique, 43
Hemidesmosomes, 74, 75–76, 96, 99
Henle's fiber layer, 211
Holocrine, 245
Horseradish peroxidase, 43, 44, 45
Hyalocytes, 181–182
Hyaloplasm, 59
Hyaluronic acid, 171–173

Intercellular connections, 73–76
Intercellular space, 76
Interference colors, 7
Intraocular pressure, elevated, 125, 127. *See also* Glaucoma

Ion milling, argon, 28
Iris, 131–141
  aging changes in, 135
  anterior border layer in, 132, 136
  dilator muscles of, 131, 132
  electron microscopy of, 132, 134, 135, 136–141
  light microscopy of, 131–132, 133
  pathology of, 135
  pigment epithelium in, 134–135, 140, 141
  sphincter muscles of, 131, 132, 133, 134, 138
  stroma and capillaries in, 132, 134, 137
  stromal pigment cells of, 134, 139

Junctions
  gap, 76, 160, 163
  intercellular, 73, 74
  tight, 194–195, 203

Keratocytes, 100–101
Koganei, clump cells of. *See* Clump cells
Kolmer's crystalloid, 210

Lacrimal gland, 248–252
  myoepithelial cells of, 249, 250, 251, 252
  secretory cells of, 249–251
Lamellae, 101
Lens, 143–154
  capsule of, 143, 144, 145–146, 149, 150
  cortex of, 146–147, 151, 152, 153
  epithelium of, 146
  nucleus (core) of, 147, 154
  structure of, 143–145
  sutures in, 147
Limbus, 109–112
Lipid inclusion bodies, 70
Lipofuscin granules, 70
Lysosomes, 56, 66–67

Maculae adherentes, 160, 163, 164. *See also* Desmosomes
Meibomian (tarsal) glands, 243–248
  cells of
    fully differentiated, 247–248
    partially differentiated, 246–247
    undifferentiated, 245–246
Melanocytes, 190, 197, 198
Melanosomes, 69, 160, 164, 201
Microfilaments, 56, 68–69
Microtubules, 56, 58, 68, 231
Microvilli, 68, 72–73, 97, 98, 103
  in retinal pigment epithelium, 205, 207, 208
Midget ganglion cells, 222
Mitochondria, 57, 63–65
Moll, glands of, 255–260
  granules in, 258–260
  myoepithelial cells of, 255–256
  secretory cells of, 257–260
Mucin-secreting cells, 252–255
Müller's cells, 174, 184, 217, 220, 225
Multilayered fenestrated sheaths, of Cloquet's canal, 179–181
Myofibrils, extraocular muscle, 264–269

Neuroectodermal components, of intraocular portion, 230–237
Neurofilaments, 231
Node of Ranvier, 241
Nuclear membrane, 55
Nuclear pores, 55, 56
Nucleolonema, 56
Nucleolus, 55, 56
Nucleus, 55–57

Ocular adnexa, glands of, 243–260. *See also specific glands*
  glands of Moll (ciliary glands), 255–260
  goblet cells, 252–255
  lacrimal gland, 248–252
  meibomian (tarsal) glands, 243–248
Oligodendrocytes, 240–241
Optic disc. *See* Optic nerve, intraocular (optic nerve head)
Optic nerve, 229–242
  intraocular (optic nerve head), 230–239

Optic nerve, intraocular (optic nerve head)—*Continued*
architectural design of, 232–236
astroglia in, 230–231, 235
axons in, 230–231
capillary cells of, 238–239
glial boundaries around, 235–237
mesodermal structures of, 238–239
neuroectodermal components of, 230–237
vitreous boundary with, 232–233
intraorbital, 239–241
Osmium tetroxide, 5, 8

Peroxidatic tracers, 43–44
Phagosomes, 194, 201, 208
Photographic emulsions, in radioautography, 34
Pia mater, 239
Pigment granules, 69–70
Pinocytotic vesicle, 102, 138
Polyribosomes, 58, 59, 60
Postfixation, 5, 6
Protein synthesis, 59–63

Radioautography, 33–36
photographic emulsions in, 34
Radioisotopes, in radioautography, 34
Ranvier, node of, 241
Retina, 205–227
blood supply of, 226, 227
electron microscopy of, 207, 208, 212, 213, 214, 218, 219, 220, 224, 225, 226
ganglion cell layer of, 221–222
glial elements of, 223, 227
internal limiting membrane of, 223, 225
neural, 206, 209–227
nuclear layer of, internal, 216–217, 219, 224
cells of
amacrine, 217, 221, 224
bipolar, 216–217
horizontal, 216
Müller, 217, 220, 225
optic fiber layer of, 222–223, 225
plexiform layer of, inner, 217, 221, 224
receptor cell layer of, 207–216, 218
inner segment of, 210, 212, 214
outer nuclear layer of, 210–211
outer plexiform layer of, 211, 215, 216, 218, 219
outer segment of, 209–210, 212
synaptic organization of, 215–216
Retinal pigment epithelium, 189, 191, 194, 195, 199, 201–204, 205, 208, 209, 221
microvilli in, 205, 207, 208
Ribosomes, 59–63
RNA, messenger, 59–63
Rods, 209
outer segments of, 194, 202
spherules of, 211, 215

Sarcomere, 264, 270
Sarcoplasmic reticulum, of extraocular muscle, 264–270
Scanning electron microscope, 21–24
function of
in electron optics, 22–24
factors affecting, 24
Schlemm's canal, 110, 113, 116, 119, 121, 122
Schwalbe's line, 110, 117
Sclera, 104–105
Sebaceous glands, 244–245
cell transformation in, 246, 247–248
Secondary electrons, in scanning electron microscopy, 22–24
Secretory cells
ciliary, 257–260
lacrimal, 249–251
mucin, 252–255
sebaceous, 244–248
Sectioning
thick, 6, 7
thin, 6, 7–8
Shadow casting, 38–41
Sonication, 27
Spherules, of rods, 211, 215
Sphincter muscles, of iris, 131, 132, 133, 134, 138
Spider cells, 232

Stereophotomicrography, 30
Stroma, and capillaries, in iris, 132, 134, 137
Sucrose density gradients, 37–38

Tarsal glands. *See* Meibomian (tarsal) glands
Tear film, 93–95, 98
  chemical composition of, 94–95
  functions of, 93–94
  layers of, 94
    aqueous, 248
    lipid, 244, 246
    mucoid, 252
Terminal bar, 73, 74
Thin sections, 6, 7–8
  staining of, 8
Tissue preparation
  for scanning electron microscopy, 24–29
    Freon-13 critical point technique of, 25–27, 29
  for transmission electron microscopy, 4–8
Tissue reclamation, in scanning electron microscopy, 28–29
Tonofilaments, 232
Tracers, electron-dense, 43–46
Transmission electron microscope
  lens systems in, 10–14
  operation of, 11–16

Ultracentrifugation, 38
Ultrasound, 27
Uveal meshwork, 116, 117, 120

Vitreociliary junction, 177, 178
Vitreolental junction, 179
Vitreoretinal junction, 173, 175, 232–233
Vitreoschisis, 185–186
Vitreous, 169–186
  basal lamina in, 173–179, 235
    detachment of, 184, 185
    function of, 174, 176
    thickening of, 183, 184
  Cloquet's canal in, 179–181
  collagen fibrils in, 169, 171–172, 174, 178, 179
  cortical tissue layer in, 181–182
  detachment of, 183, 184
  disc boundary with, 232–233
  gel, 169–173
  liquid, 169, 171–173
    ciliary body formation of, 157
  multilayered fenestrated sheaths in, 179–181
  pathology of, 183–186. *See also specific conditions, e.g.,* Glia cell detachment; Vitreoschisis
  strands in, 184–185

Wing cell layer, 96

Zeis, glands of, 244. *See also* Sebaceous glands
Zonula occludens, 194–195, 203
Zonules of Zinn, 144, 146, 149, 150

Index

Acetate topical steroids, 108
Adenine arabinoside, 54–58
  in deep herpetic disease, 56–58
  in viral keratoconjunctivitis, 55–56
    comparison to IDU, 56
Adenoviral keratoconjunctivitis, 115, 134–135
Adrenocortical hormones, 103–104. *See also* Corticosteroids; Corticosteroid therapy
Alcohol topical steroids, 108
Alkali-burned cornea, 229–230, 237
Amphotericin B, 79
  results of therapy with, 84
Anesthesiometer, corneal, 41
Anterior segment disease, heparin therapy in, 235–242
Antibiotic therapy, in bacterial ulcerative keratitis. *See* Bacterial ulcerative keratitis
Antibiotic-corticosteroid therapy, 128–132
Antimetabolite therapy, in disciform keratitis, 49
Antiviral agents, 42–44, 53–62
Antiviral ocular inserts, 59–61
Aqueous-deficient dry eye, 145, 148–150. *See also* Keratoconjunctivitis sicca
Artificial tears. *See* Tear substitutes
Atopic keratoconjunctivitis. *See* Keratoconjunctivitis, atopic

Bacitracin, for bacterial corneal keratitis, 14, 15, 18, 21
Bacterial corneal ulcers. *See* Bacterial ulcerative keratitis
Bacterial ulcerative keratitis, 1–28, 31–36
  antibiotic therapy for
    agents in, 12–16
    concentrations and dosages in, 15
    initial, 12–23
    intravenous, 19
    modification of, after identification of organism, 23–26
    subconjunctival, 17, 19, 20–21, 32–33
    systemic, 31–32
    topical, 17, 18, 32–33, 34–36
  clinical diagnosis of, 1–2
  collagenase inhibition therapy for, 231–232
  laboratory studies of, 2–6
  organisms in, 6–12
  structural changes in, 11–12
Bandage lens. *See* Soft contact lens
Blennorrhea, inclusion, 99–100
Blowout patch-graft, corneal, 72, 88
Bullous keratopathy, 162
  soft contact lens in, 179–184
    for nonvisual symptoms, 180–182
    for visual symptoms, 183–184

Carbenicillin, for bacterial corneal keratitis, 15, 16, 18, 20, 21
Cataract, corticosteroid therapy and, 111, 142
Chalazion, 196
Chlamydia infections, 93–101
  diagnosis of, 94–100
Cocaine, topical, 108

Collagen diseases, systemic, keratoconjunctivitis sicca and, 145
Collagenase
activity and inhibition of, dynamics of, 226–227
in animal tissues, 225–226
cell origin of, 227–228
in pathogenesis of corneal ulcers, 228–229
in treatment of corneal ulcers, 225–233
from alkali burns, 229–230
from bacterial infection, 231–232
with dry eye, 233
from herpes infection, 231
Collyria, soft contact lens and, 189–190
Conjunctival flap, 65–67
in keratomycosis, 83–86, 87–90
Conjunctivitis
follicular. *See* Follicular conjunctivitis
hay fever, 196, 200–201
inclusion, 98–100
adult oculogenital, 98–99
newborn, 99–100
vernal, 196, 201–203
Contact dermatitis, 196, 203–204
Contact lens, soft. *See* Soft contact lens
Cornea
bacterial ulcers of. *See* Bacterial ulcerative keratitis
fungal infections of. *See* Keratomycosis
ischemic necrosis of, therapy, 236, 238–240, 241
peripheral ischemic necrosis of, 236, 238–240, 241
Corneal blowout patch-graft, 72, 88
Corneal dystrophies, 161–162
Corneal edema, 118–119
Corneal erosion, recurrent, 155–164
idiopathic, 164
postinflammatory, 160–161
posttraumatic, 155–160
acute phase of, 159
basement membrane synthesis and, 158
chronic phase of, 159
clinical signs of, 155–157
history in, 157
management of, 159–160
pathogenesis of, 158–159
in Reis-Bücklers disease, 161, 162
secondary, to exposure and drying, 163
secondary, to underlying keratopathy, 160–164
Corneal grafts. *See* Keratoplasty
Corneal inflammation
classification of, 125–127
severity gradient of, 127
Corneal pathogens, sensitivity of, to antibiotics, 12–13
Corneal perforation. *See* Perforation, corneal
Corneal scraping, 4–5
Corneal transplant. *See* Keratoplasty
Corneal wounds, penetrating, soft contact lens and, 188–189
Corticosteroid allergy, 143
Corticosteroid therapy, 103–120, 125–144
administration of, 108–109
in bacterial ulcerative keratitis, 26
cataract and, 111, 142
in coalescent keratitis
infectious, 128–132
noninfectious, 132–133
complications of, 109–111, 135–143
in corneal edema, 118–119
in corneal surgery, 119–120, 135
Cushing's syndrome and, 142–143
in diffuse keratitis
infectious, 133–135
noninfectious, 135
in disciform keratitis, 48–49
dose-response relationships in, 104, 107
in erythema multiforme, 219
in fungus disease, 139–140
glaucoma and, 110–111
healing retardation by, 110, 141

in herpes simplex keratitis, 109–110, 112–113
failure of, in recurrent herpetic keratitis, 67
in herpes zoster infections, 139
indications for, 125–126
infection and, 109–110, 138–139
in interstitial keratitis, 116–117
in keratoconjunctivitis, 115–116
mechanisms of action in, 104
ocular hypertension and, 141–142
in ocular immune disease, 197–198
in phlyctenulosis, 117
in rosacea keratitis, 118
in staphylococcal marginal corneal ulceration, 117–118
subconjunctival, 109
systemic, 109
in Thygeson's superficial punctate keratitis, 118
topical, 108–109
in vaccinia keratitis, 113–114
in varicella-zoster keratitis, 114–115
vascular ischemia and, 140–141
in vernal keratitis, 116
Corticosteroids
allergy to, 143
ophthalmic, 105–106
therapeutic potencies of, 107
transport and penetration of, 107–108
Culture media for organism identification, 3–5
Curettage, corneal, 79, 83. *See also* Debridement, corneal
Cushing's syndrome, corticosteroid therapy and, 142–143
Cyanoacrylate adhesive, for soft contact lens, 72
Cysteine collagenase inhibition, 226, 229–232
for alkali burns of cornea, 229–230
for bacterial corneal ulcers, 231–232
for herpetic corneal ulcers, 231
for ulcers associated with dry eyes, 233

Debridement, corneal, 42–43. *See also* Curettage, corneal
chemical, 43, 44–45
mechanical, 42–43, 50
Dendritic ulcerations, in herpetic keratitis, 39, 40
Dermatitis, contact, 196, 203–204
Descemetocele, 70
Diplococcus pneumoniae corneal ulcers, 6, 8, 11, 23
Disciform keratitis, 47–49
pathogenesis of, 47–48
therapy of, 48–49
Discoid lupus erythematosus, 196, 206
Disodium ethylenediaminetetraacetate. *See* EDTA
Dry eye, 145–152. *See also* Keratoconjunctivitis sicca
aqueous-deficient, 145, 148–150
collagenase inhibition therapy for, 232
mucin-deficient, 146, 150–151
(soft) contact lens in, 150, 171, 175
Dystrophies, corneal, 161–162

Eczema, ocular atopic, 198–200
signs and symptoms of, 198–199
treatment of, 199–200
Edema, corneal, 118–119
EDTA, in bacterial ulcerative keratitis therapy, 26, 226–227
Endophthalmitis phacoanaphylactica, 196
Enterobacteriaceae, in ulcerative keratitis, 10–11, 12
Epidemic keratoconjunctivitis, 115, 134–135
Epidermal necrolysis, toxic, 214, 217–218
treatment of, 218–219
Episcleritis, 196

Epithelial erosions, in herpetic disease, 49–51
therapy of, 50–51
Erosion, recurrent corneal. *See* Corneal erosion, recurrent
Erythema multiforme, 196, 213–219. *See also* Epidermal necrolysis, toxic
clinical manifestations of, 215–218
epidemiology of, 215
etiology of, 215
major, 214, 216, 217
minor, 214, 215–216
target lesion in, 216
treatment of, 218–219
variants of, 213–214

Follicular conjunctivitis
acute, 93–94
chronic, 94. *See also* Inclusion conjunctivitis; Trachoma
Folliculosis, 93
Fungal corneal infections. *See* Keratomycosis

Gentamicin, for bacterial corneal keratitis, 14, 15, 16, 17, 20, 21
Glaucoma, corticosteroid therapy and, 110–111
Glucocorticoids. *See* Corticosteroid therapy; Corticosteroids
Gram's stain, of corneal scrapings, 19, 22, 27

Hay fever conjunctivitis, 196, 200–201
Healing, wound, corticosteroid therapy and, 110, 141
Heparin
in anterior segment disease, 235–242
biochemistry and pharmacology of, 235–236
clinical experience with, 238–240, 241
clinical uses of, 236
complications of, 240, 242
derivation of, 238
dosages of, 237, 238
parenteral administration of, 237
subconjunctival administration of, 236–237, 239–242
topical administration of, 238
Herbert's pits, 96, 97
Herpes simplex, ocular. *See also* Disciform keratitis; Herpetic keratitis
photodynamic inactivation of virus, 46
Herpetic keratitis, 39–51. *See also* Disciform keratitis
following corneal transplant, 119–120
diagnosis of, 39–42
epithelial, 39–46
epithelial erosions in, 49–51, 160–161
photodynamic inactivation of, 46
recurrent
conjunctival flap for, 66
interferon and, 58–59
with superficial stromal involvement, 47
therapy for, 42–46
collagenase inhibitors in, 231
corticosteroids in, 109–110, 112–113, 128–131
new developments in, 53–62
soft contact lens in, 169–171, 185–186
Herpetic uveitis, therapy for, 56–58
Hydrocortisone. *See* Corticosteroid therapy; Corticosteroids
Hydrophilic contact lens. *See* Soft contact lens
Hypopyon, 2, 8, 11, 77
Hypoxanthine arabinoside, 54–58

Idoxuridine (IDU) therapy, 42–44, 53
comparison of, to adenine arabinoside, 56, 57
toxicity reactions in, 44, 45, 67, 160–161

Idoxuridine-corticosteroid therapy, 129, 130
IDU. *See* Idoxuridine therapy
Immune diseases, ocular, 193–210. *See also specific diseases*
  immunological properties of, 194–195
  treatment of, principles, 195–198
Immunological mechanisms, 193–194
Inclusion blennorrhea, 99–100
Inclusion conjunctivitis, 98–100
  adult oculogenital, 98–99
  newborn, 99–100
Interferon, 58–59
Interstitial keratitis, 116–117, 196
Iontophoresis, 35
Ischemic necrosis of cornea, heparin therapy of, 236, 238–240, 241

Keratectomy, 83
  superficial, 79, 82
Keratitis
  active surgical therapy of, 65–74
  bacterial ulcerative. *See* Bacterial ulcerative keratitis
  coalescent, 126
    infectious, 128–132
    noninfectious, 132–133
  diffuse, 126
    infectious, 133–135
    noninfectious, 135
  disciform. *See* Disciform keratitis
  fungal. *See* Keratomycosis
  herpetic. *See* Herpetic keratitis
  infiltrative stromal, 128–135
  interstitial, 116–117, 196
  punctate, 196
  rosacea, 118
  Thygeson's superficial punctate, 118
  vaccinia, 113–114
  varicella-zoster, 114–115
  vernal, 116
Keratitis sicca, 196
Keratoconjunctivitis
  adenoviral, 115, 134–135
  atopic, 115–116, 196, 198–200
  epidemic, 115, 134–135
Keratoconjunctivitis sicca, 145. *See also* Dry eye
  punctum occlusion for, 149–150
  secondary infection in, 150
  soft contact lens in, 150, 171, 187
  treatment considerations in, 148–151
Keratoconus, soft contact lens in, 187–188
Keratomycosis, 75–91
  clinical diagnosis of, 76–77
  corticosteroid therapy in, 139–140
  diagnosis
    differential, 77–78
    laboratory, 78–79
  epidemiology of, 75
  trauma and, 75, 77
  treatment of, 79–90
    drug, 79–83, 132
      results of, 84
    surgical, 83–87
      causes of failure of, 87–90
Keratoplasty. *See also* Corneal blow-out patch-graft
  immunological rejection following, 196, 207–209
  penetrating, 69–70, 73
    for keratomycosis, 86–90
  segmental lamellar, 71
Kveim reaction, 205

Lavage, constant, antibiotic therapy, 34–35
Low-temperature probes to corneal surface, 45–46
Löwenstein's culture medium, 4
Lupus erythematosus, 196, 206–207

Methicillin, for bacterial corneal ulceration, 14, 15, 20, 21
Mooren's ulcer, 65, 68, 141, 228
Moraxella corneal ulcers, 9–10, 12, 16, 23
Mucin-deficient dry eye, 146, 150–151
Mycobacterium fortuitum, 10–11
Mycostatin. *See* Nystatin

Mycotic corneal infection. *See* Keratomycosis

Natamycin. *See* Pimaricin
Necrolysis, toxic epidermal. *See* Epidermal necrolysis, toxic
Neisseria corneal infections, 10, 11, 12, 14, 23, 70–71
Nystatin, 79, 82, 84

Ocular herpes simplex. *See* Herpetic keratitis
Ocular hypertension. *See also* Glaucoma
  corticosteroid therapy and, 141–142
Ocular immune diseases. *See* Immune diseases, ocular; *specific diseases*
Oculogenital inclusion conjunctivitis, 98–99
Ocusert, 59–61, 98

Patch-graft, corneal blowout, 72, 88
Pemphigoid, benign mucosal, 196, 211–213
  mucosal and cutaneous involvement in, 211–212
  ocular involvement in, 212–213
  treatment of, 219–220
Penicillin G, for bacterial ulcerative keratitis, 12, 13, 15, 18, 20, 21, 23
Penicillin-resistant bacteria, in corneal ulcers, 12, 13, 23
Perforation, corneal
  threatened, 67–71
  true, 72–74
Phlyctenulosis, 117, 196
Phosphate topical steroids, 108
Pimaricin, 79, 82
  results of therapy with, 84
Polyvinyl alcohol, in tear substitutes, 147–148
Proflavin, 46
Pseudomonas aeruginosa corneal infection, 7, 9, 10, 11–12, 232
Pseudomonas fluorescens corneal infection, 9
Pseudomonas keratouveitis, 68, 69
Punctate keratitis, 196
  Thygeson's superficial, 118
Punctum occlusion, 149–150

Reis-Bücklers disease, 161, 162
Rejection, of corneal transplants, 207–209
Rosacea keratitis, 118

Sarcoidosis, 196, 204–206
Scalded-skin syndrome, 214. *See also* Erythema multiforme
Scleritis, 196
Scraping, cornea, 4–5
Serratia marcescens, as ocular pathogen, 10
Sjögren's syndrome, 196. *See also* Dry eye; Keratoconjunctivitis sicca
Soflens, 169, 179–190
  fitting technique for, 180, 184–185
  modifications of, and therapeutic effectiveness, 186–187
Soft contact lens, 167–176, 179–190. *See also* Soflens; Softcon lens
  adhesive, 72
  in bullous keratopathy, 179–184
    for nonvisual symptoms, 180–182
    results of, 180–182
    for visual symptoms, 183–184
  for chronic ulcer, 66
  complications of, 175, 181–182
  in corneal wounds (penetrating), 188–189
  for epithelial erosions in herpetic disease, 50
  fitting techniques for, 173–175
    in bullous keratopathy, 180
    in superficial, noninfected indolent ulcers, 184–185
  in keratoconjunctivitis sicca, 187
  in keratoconus, 187–188
  mechanism of effect of, 183–184
  permeability of, to drugs, 69

preservatives and, 189–190
pump mechanism of, 169
in superficial, noninfected indolent ulcers, 184–187
fitting technique for, 184–185
with modifications, 186–187
results of, 185–186
therapeutic functions of, 168–173
drug delivery, 169, 171
improving visual acuity, 172–173
pain relief, 172
protection, 168
splinting, 168
wetting, 171
for threatened corneal perforation, 68
for true corneal perforation, 72
visual improvement by, 172–173, 183–184
Softcon lens, 167–176
schematic diagram of, 173
Staphylococcal marginal corneal ulceration, 117–118
Staphylococcus aureus corneal infection, 6–7, 8, 134
Staphylococcus epidermidis corneal infection, 6–7
Stevens-Johnson syndrome, 146, 149, 151
Streptococcus, as corneal pathogen, 7, 23
Surfactants, 108
Sustained-release pellets, 35–36
Symblepharon, 212, 213
Sympathetic ophthalmia, 196
Systemic lupus erythematosus, 196, 206–207

Tear substitutes, 145–152
antibiotic, preparation of, 18
in benign mucosal pemphigoid therapy, 219–220
benzalkonium chloride in, 147, 148
ingredients of, principal, 147
methylcellulose in, 147
pump for, 220
sample regimens using, 148–149
in treatment of dry eyes, 145–152
Thygeson's superficial punctate keratitis, 118
Thyroid exophthalmos, 196
Toxic epidermal necrolysis. *See* Epidermal necrolysis, toxic; *see also* Erythema multiforme
Trachoma, 95–98, 196
classification of, 97
clinical signs of, 95–97
epidemiology of, 98
treatment of, 97
Transplant, lamellar corneal, 69, 87–90. *See also* Keratoplasty
Trauma
keratomycosis and, 75, 77
recurrent corneal erosion and, 155–160

Ulcers
bacterial corneal. *See* Bacterial ulcerative keratitis
catarrhal, 117–118
chronic nonhealing corneal, 65–67
fungal corneal. *See* Keratomycosis
superficial, noninfected indolent, 184–187
treatment of, with collagenase inhibitors, 225–233
Uveitis. *See also Pseudomonas* keratouveitis
anterior, 196
herpetic. *See* Herpetic uveitis
posterior, 196

Vaccinia keratitis, 113–114
Varicella-zoster keratitis, 114–115
Vernal conjunctivitis, 196, 201–203
Vernal keratitis, 116

Wessely reactions, 133

Xerophthalmia, 150–151

Zoonoses, *Chlamydia*, 100